<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Nieto Y</submitter><pubmed_abstract>There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL) undergoing autologous hematopoietic stem cell transplantation (ASCT). We analyzed 222 patients aged 0-39 years undergoing first ASCT for NHL between 2000 and 2020. The most common histological subtypes were DLBCL (44%), T-NHL (19%) and PMBCL (19%). Younger patients (age ≤ 25) had lower incidence of DLBCL and higher incidence of PMBCL and T-NHL compared to older patients (> 25 years) (P = 0.02). None of the younger patients had DH)/DE DLBCL, as compared to 14 patients in the older group (18%, P = 0.07). Younger patients had numerically better 15-year post-transplant PFS (67% vs. 54%) and OS (71% vs. 62%) compared to older patients, without statistically significant differences (P = 0.19 and P = 0.24, respectively). In MVA, not achieving a CR prior to ASCT was independently predictive of worse PFS (P &lt; 0.0001). DH/DE status was an independent adverse predictor of PFS in MVA (HR 5.8, p = 0.03). 10 patients(4.5%) (all aged > 25 years) developed SPM Patients aged ≤ 25 years presented a distinct NHL histology as compared to older CAYA patients. Disease status at ASCT was predictive of both PFS and OS. DH/DE status was an adverse predictor of PFS.</pubmed_abstract><journal>Research square</journal><pagination>rs.3.rs-2531406</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9934761</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant.</pubmed_title><pmcid>PMC9934761</pmcid><pubmed_authors>Srour S</pubmed_authors><pubmed_authors>Champlin R</pubmed_authors><pubmed_authors>Pasvolsky O</pubmed_authors><pubmed_authors>Nieto Y</pubmed_authors><pubmed_authors>Ramdial J</pubmed_authors><pubmed_authors>Kebriaei P</pubmed_authors><pubmed_authors>Mahadeo K</pubmed_authors><pubmed_authors>Popat U</pubmed_authors><pubmed_authors>Petropoulos D</pubmed_authors><pubmed_authors>Cuglievan B</pubmed_authors><pubmed_authors>Ghanem S</pubmed_authors><pubmed_authors>Tewari P</pubmed_authors><pubmed_authors>Hosing C</pubmed_authors><pubmed_authors>Shpall E</pubmed_authors><pubmed_authors>Bassett R</pubmed_authors><pubmed_authors>Khazal S</pubmed_authors><pubmed_authors>Qazilbash M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant.</name><description>There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL) undergoing autologous hematopoietic stem cell transplantation (ASCT). We analyzed 222 patients aged 0-39 years undergoing first ASCT for NHL between 2000 and 2020. The most common histological subtypes were DLBCL (44%), T-NHL (19%) and PMBCL (19%). Younger patients (age ≤ 25) had lower incidence of DLBCL and higher incidence of PMBCL and T-NHL compared to older patients (> 25 years) (P = 0.02). None of the younger patients had DH)/DE DLBCL, as compared to 14 patients in the older group (18%, P = 0.07). Younger patients had numerically better 15-year post-transplant PFS (67% vs. 54%) and OS (71% vs. 62%) compared to older patients, without statistically significant differences (P = 0.19 and P = 0.24, respectively). In MVA, not achieving a CR prior to ASCT was independently predictive of worse PFS (P &lt; 0.0001). DH/DE status was an independent adverse predictor of PFS in MVA (HR 5.8, p = 0.03). 10 patients(4.5%) (all aged > 25 years) developed SPM Patients aged ≤ 25 years presented a distinct NHL histology as compared to older CAYA patients. Disease status at ASCT was predictive of both PFS and OS. DH/DE status was an adverse predictor of PFS.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-19T02:45:13.87Z</modification><creation>2025-04-07T13:05:18.011Z</creation></dates><accession>S-EPMC9934761</accession><cross_references><pubmed>36798261</pubmed><doi>10.21203/rs.3.rs-2531406/v1</doi></cross_references></HashMap>